logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9056867 B1

PDFFull Text
Date of Patent:
Jun. 16, 2015

Filed:

Sep. 14, 2012

N-substituted heterocyclyl carboxamides

Applicants:

Kamlesh Jagdis Bala, Horsham, GB;

Emma Budd, Horsham, GB;

Lee Edwards, Horsham, GB;

Catherine Howsham, Horsham, GB;

Darren Mark Legrand, Horsham, GB;

Roger John Taylor, Horsham, GB;

Inventors:

Kamlesh Jagdis Bala, Horsham, GB;

Emma Budd, Horsham, GB;

Lee Edwards, Horsham, GB;

Catherine Howsham, Horsham, GB;

Darren Mark LeGrand, Horsham, GB;

Roger John Taylor, Horsham, GB;

Assignee:

NOVARTIS AG, Basel, CH;

Attorney:

Qian Zhang

Primary Examiner:

Brian McDowell

Int. Cl.
CPC ...
A61K 31/4427 (2006.01); C07D 487/04 (2006.01); A61K 31/415 (2006.01); A61K 31/4439 (2006.01); A61K 31/497 (2006.01); A61K 45/06 (2006.01); A61K 31/4985 (2006.01); A61K 31/5377 (2006.01); A61K 31/444 (2006.01); C07D 231/40 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 413/14 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/415 (2013.01); A61K 31/4439 (2013.01); A61K 31/497 (2013.01); A61K 45/06 (2013.01); A61K 31/4985 (2013.01); A61K 31/5377 (2013.01); A61K 31/444 (2013.01); C07D 231/40 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 413/14 (2013.01);
Abstract

A compound of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, A, B, D and E are all as defined herein. The compounds modulate the activity of CFTR and are useful in the treatment of inflammatory or obstructive airways diseases or mucosal hydration, including, for example cystic fibrosis. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Find Patent Forward Citations

Loading…